
Cat. #161857
RPE1 PBRM1 KO2
Cat. #: 161857
Availability: 8-10 weeks
Organism: Human
Tissue: retinal epithelium
Model: Genetically modified ; immortalised non-cancer cells
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Jessica Downs, Karen Lane
Institute: The Institute of Cancer Research
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: RPE1 PBRM1 KO2
- Parental cell: RPE1-hTERT
- Clone: 2 (also called cloneB16)
- Organism: Human
- Gender: Female
- Tissue: retinal epithelium
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Genetically modified ; immortalised non-cancer cells
- Model description: PBRM1 knockout
- Crispr: Yes
- Conditional: No
- Products or characteristics of interest: Gene loss-of-function, chromatin-remodelling, DNA damage, cell cycle response, regulation of t-cell-mediated cell killing.
- Description: RPE1-hTERT cell line knockout for PBRM1 (clone 2, also called B16). This cell line was generated using CRISPR-Cas9 engineering to create a loss of function mutation in the indicated subunit of the SWI/SNF chromatin remodelling complex. The cell line was validated using Sanger sequencing, immunofluorescence, and proteomic analysis.
- Application: Chromatin remodelling biology studies
- Biosafety level: 1
- Cellosaurus id: CVCL_4388
Applications
- Application: Chromatin remodelling biology studies
Handling
- Format: Frozen
- Growth medium: DMEM /Ham F12 nutrient mixture + 10S + 1% Penicillin/Streptomycin
- Temperature: 37C
- Atmosphere: 5% CO2 in air
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: 1% Penicillin/Streptomycin
- Str profiling: See Cellosaurus profile of parental cell line
References
- Unpublished
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)

